Updated Guidelines Significantly Expand Patient Access to Centinel Spine’s prodisc® L Lumbar Total Disc Replacement

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

prodisc® L Lumbar Total Disc Replacement system by Centinel Spine shows a significant expansion to patient access. This represents an additional 9.2 million covered lives and is a result of an update to medical necessity guidelines by National Imaging Associates (NIA), a Magellan Health Company, to now include a positive coverage policy recommendation for lumbar TDR.

NIA Magellan provides third-party prior authorization services to U.S. insurers. Nine major commercial payers that follow NIA Magellan’s clinical coverage guidelines have now started to cover lumbar TDR, including BCBS of Florida & S. Carolina, Harvard Pilgrim and Tufts, among others. Centinel Spine remains the only company in the world with an FDA-approved lumbar TDR device that has been clinically reviewed and found safe and effective for two-level use.

“This recent announcement of expanded coverage for lumbar TDR demonstrates the important progress being made in this area,” stated Centinel Spine CEO Steve Murray. “We are encouraged that NIA Magellan recognizes the large body of clinical evidence that demonstrates lumbar TDR to be a safe and effective procedure for select patients,” continued Murray. “This coverage expansion represents an excellent opportunity for surgeons to provide more patients with a broader spectrum of treatment options and ensure the delivery of the best spine care possible.”

Centinel Spine stands alone as the only company with FDA-approved cervical and lumbar total disc replacement devices. New developments to the family of products include the recent FDA approval of two-level indications for the prodisc L Lumbar Total Disc Replacement system and a recently-initiated clinical trial comparing the prodisc C Vivo and prodisc C SK devices with an approved cervical TDR product as a control, in order to validate their safety and effectiveness in an FDA IDE study.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.